Early stage diabetic therapies continue to attract licensing partners
Date of publication: June 11, 2010
Deal making activities for early stage diabetic compounds continue to remain buoyant with the news that Forest Laboratories and TransTech Pharma have announced a licensing agreement valued at over $1 billion. See this deal illustrated on our Partnering 2010 Scorecard
The lead compound TTP399 promise to provide major therapeutic advances in the treatment of diabetes due to its ability to improve glycemic control without exerting increasing additional pressure on the pancreas.
However, the announcement by Forest and TransTech is only the latest in a series of small molecule-based early stage deals that have been reported recently for the treatment of diabetes.
CureDM and Sanofi-Aventis have announced in April a $335million licensing agreement for the eraly stage diabetic compound Pancreate(TM).
In addition, Eli Lilly and Transition Therapeutics have also announced a $251 million licensing agreement for a series of pre-clinical diabetes compounds.
All three early stage deals are structured to include an upfront, milestone and royalty payments and illustrate that early stage diabetic compounds continue to remain pivotal to pharmaceutical companies who are actively seeking to expand their portfolio of products.
Tim Martin